Pembrolizumab for Early Triple-Negative Breast CancerPeter Schmid, Joyce O’Shaughnessy, Javier Cortés et al.|New England Journal of Medicine|2020Cited by 3.1k
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trialSherene Loi, Christos Sotiriou, Stefan Michiels et al.|Annals of Oncology|2014Cited by 1.3k
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017Giuseppe Curigliano, Andrew Tutt, Peter Dubsky et al.|Annals of Oncology|2017Cited by 1.3k
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upSibylle Loibl, Nadia Harbeck, Fabrice André et al.|Annals of Oncology|2023Cited by 830
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021Harold J. Burstein, Binghe Xu, Giuseppe Curigliano et al.|Annals of Oncology|2021Cited by 799